Addex spin-out Neurosterix completes Phase 1 studies of schizophrenia drug NTX-253, plans Phase 2

Neurosterix, an Addex spin-out, completed Phase 1 clinical studies of NTX-253 for schizophrenia, with single and multiple ascending dose studies providing safety and pharmacokinetic data. The company plans Phase 2 schizophrenia development.

Detected & updated continuously · Source: Nebula